Calcitonin gene-related peptide (CGRP) is probably the most potent vasodilator in cerebral
circulation. Forty years after its discovery, the new CGRP-targeted therapy monoclonal …

Abstract Calcitonin Gene-Related Peptide (CGRP) plays a pivotal role in migraine
pathophysiology. Two types of CGRP function-blocking modalities, monoclonal antibodies …

Migraine is the second most disabling disorder across all age groups worldwide. Since
2018, two classes of drugs that inhibit the actions of calcitonin gene-related peptide (CGRP) …

Calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide found mostly in
peptidergic sensory C-fibers, has been suggested to be implicated in the pathogenesis of …

Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as
antagonists of the CGRP receptor or ligand. They can be divided into monoclonal antibodies …

Several lines of evidence pointed to an important role for CGRP in migraine. These included
the anatomic colocalization of CGRP and its receptor in sensory fibers innervating pain …

Migraine is a debilitating disease whose clinical and social impact is out of debate.
Tolerability issues, interactions, contraindications, and inefficacy of the available …

Migraine is a highly prevalent, complex neurological disorder. The burden of disease and
the direct/indirect annual costs are enormous. Thus far, treatment options have been …

Introduction Migraine is the leading cause of years lived with disability in people under 50.
Electrophysiological phenomena at the basis of prodromal and headache attack phases and …

Migraine is a debilitating neurological condition that involves the neuropeptide calcitonin
gene-related peptide (CGRP). An exciting development is the recent FDA approval of the …